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Abstract
Background: Amoebic liver abscess (ALA) is the most common clinical manifestation of extraintestinal amoebiasis
especially in developing countries, causing up to 100 000 fatal cases annually. Accurate and early diagnosis is
important to prevent the disease complications, however its diagnosis still poses many challenges due to the
limitations of the available detection tools. Pyruvate phosphate dikinase (PPDK), an excretory-secretory protein of
E. histolytica, has been reported as a potential diagnostic marker for ALA, hence it may be exploited in the development
of a new test for ALA.
Methods: Recombinant PPDK (rPPDK) was expressed, purified and evaluated by Western blot. In parallel, recombinant
galactose-and-N-acetyl-D-galactosamine inhibitable lectin (Gal/GalNAc lectin) was produced and tested similarly. The
protein identity was confirmed by analysis using MALDI-TOF/TOF. A lateral flow dipstick (LFD) test using rPPDK was
subsequently developed (rPPDK-LFD) and evaluated for serodiagnosis of ALA.
Results: rPPDK was expressed as soluble protein after 4 hours of induction with 1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) at 30°C. Purification using nickel-nitrilotriacetic acid (Ni-NTA) resin yielded 1.5 mg of rPPDK from 1 L of
culture with estimated molecular mass of 98 kDa on SDS-PAGE. Western blots using sera from patients with ALA,
healthy individuals and other diseases probed with anti-human IgG4-HRP showed the highest sensitivity (93.3%) and
specificity (100%); as compared to blots using IgG and IgG1 as secondary antibodies. Moreover, rPPDK showed better
specificity when compared to rGal/GalNAc lectin. In the development of the LFD test, the optimum amount of rPPDK
was 0.625 μg per dipstick and the optimum working concentration of colloidal gold conjugated anti-human IgG4 was
optical density (OD) 5 (1.7 μg of anti-human IgG4). Evaluation of rPPDK-LFD using ALA patients and controls serum
samples showed 87% diagnostic sensitivity and 100% specificity.
Conclusion: The developed rPPDK-LFD showed good potential for rapid diagnosis of ALA, and merit further multicentre
validation using larger number of serum samples.
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Background
The enteric protozoan parasite, Entamoeba histolytica is
the causative agent of amoebiasis which affects 40–50
million individuals worldwide [1]. About 10% of infected
people risk developing symptomatic invasive amoebiasis
namely amoebic colitis and extraintestinal amoebiasis.
About 40 000 to 100 000 of fatal cases are recorded an-
nually, most cases are due to amoebic liver abscess
(ALA) which resulted from the hematogenous spread of
the E. histolytica trophozoites from intestine to liver
through the portal vein [2,3]. Other than variability in
clinical manifestations [4], imaging techniques such as
ultrasound, computed tomography, and magnetic reson-
ance may not distinguish ALA from pyogenic liver ab-
scess [5]. Therefore, serological tests are important for
detection of E. histolytica infection to support clinical
and radiological findings.
Currently, commercially available E. histolytica anti-
body detection assays include RIDASCREEN Ent-
amoeba IgG ELISA (R-Biopharm AG, Darmstadt,
Germany), IHA Cellognost® Amoebiasis kit (Dade
Behring Marburg GmbH, Marburg, Germany) and
Novagnost Entamoeba IgG (NovaTec Immunodiag-
nostica GmbH, Dietzenbach, Germany); these used
complex mixture of native E. histolytica proteins from
trophozoites [6,7]. Such tests are useful in detecting
anti-E. histolytica antibodies in serum samples in
non-endemic areas, however they often detect past in-
fections when used in endemic areas due to the high
level of background antibodies against the plethora of
proteins in the native antigen [8,9]. Among the com-
mercially available stool antigen tests, TechLab E. his-
tolytica II ELISA (TechLab, Blacksburg, VA, USA) has
been evaluated for detection of E. histolytica Gal/Gal-
NAc lectin antigen in serum samples from patients
with ALA [4,10]. However variable sensitivities have
been observed depending on whether treatment had
been initiated [9]. DNA-based techniques are avail-
able, however the usage is limited to reference labora-
tories; moreover, it requires an invasive procedure to
collect the pus samples [11-13]. Therefore a conveni-
ent, rapid and sensitive serological detection test is
needed to fulfil the gap in diagnosis of ALA.
Previously we have showed the promising perform-
ance of E. histolytica pyruvate phosphate dikinase
(PPDK) as a diagnostic marker [14], thus the present
study was performed to produce the recombinant pro-
tein of PPDK (rPPDK) and analyze the diagnostic sensi-
tivity and specificity by Western blot. As a comparison,
recombinant Gal/GalNAc lectin (rGal/GalNAc lectin)
was also produced and similarly evaluated. Subse-
quently rPPDK was used in the development of lateral
flow dipstick (LFD) test for the detection of specific
antibodies in patients with ALA.
Methods
Ethics statement
The serum samples were collected from Hospital
Universiti Sains Malaysia, Kubang Kerian, Kelantan,
Hospital Sultanah Bahiyah, Alor Setar, Kedah and
General Hospital Pulau Pinang. Serum samples from
healthy volunteers and other diseases were obtained
from our existing serum bank. Written informed
consent for participation in the study was obtained
from participants or, where participants are children,
a parent or guardian. This study was approved by the
Ethics Committee of the Universiti Sains Malaysia,
Malaysia (ref: USMKK/PPP/JEPcm[213.3(10)]).
Serum samples
Thirty serum samples from patients with ALA were
divided into two groups namely Group A comprised 15
samples which were seropositive (for anti-E. histolytica
antibody) and their liver abscesses were positive for E.
histolytica DNA using real-time PCR; Group B com-
prised 15 samples which were seropositive but their liver
abscess samples were unavailable for DNA analysis.
Seropositivity was determined using RIDASCREEN
Entamoeba histolytica IgG ELISA kit (R-Biopharm AG,
Germany). Meanwhile, detection of E. histolytica DNA
in the liver abscess aspirates was performed using real-
time PCR, as published in our previous report [15].
Twenty sera from healthy individuals were used as
negative control. In addition, control samples included
sera from patients with other diseases (n = 20); i.e. toxo-
plasmosis (n = 2), malaria (n = 4), hydatidosis (n = 2),
pyogenic liver abscess (n = 5), typhoid (n = 1), leptospir-
osis (n = 4) and filariasis (n = 2). All control sera tested
negative with the above ELISA kit.
Expression and purification of the recombinant proteins
The PPDK gene (Accession no: EHI009530) and C-
terminus of Gal/GalNAc lectin gene (Accession no:
AF337950) were each custom-cloned into the expression
vector pET28a(+) (Novagen, Darmstadt, Germany). This
vector is under control of promoter recognized by T7
RNA polymerase and contains a metal binding domain
of six histidine residues for use in the affinity purifica-
tion of the recombinant protein. Five microliters of each
constructed plasmid was transformed into Escherichia
coli strain BL21 (DE3) (Invitrogen, New York, USA)
using CaCl2 method and the transformants were incu-
bated in 200 μl of Super Optimal Broth (SOB) medium
at 37°C for 1 hour prior to plating. Protein expression
was performed by growing a single colony of pET28a/
PPDK and pET28a/Gal-GalNAc lectin in Terrific Broth
(TB) medium supplemented with 50 μg/ml of kanamy-
cin at 37°C overnight. TB medium containing antibiotics
was inoculated by overnight culture and grown at 37°C
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with vigorous shaking until the OD600 reached 0.4 to
0.6. Subsequently, the culture was induced by 1 mM
IPTG (Thermo Scientific Pierce, Massachusetts, USA)
for 4 hours at 30°C. To verify the presence of the histi-
dine fusion recombinant protein, the rPPDK and rGal/
GalNAc lectin protein were separated by SDS-PAGE,
transferred to nitrocellulose membrane and analyzed by
Western blot using anti-His conjugated to horseradish
peroxidise (HRP) (Novagen, Germany) at a 1:5000 dilu-
tion. E.coli transformed with expression vector, pET28a(+)
without insert was used as negative control.
Cells were harvested from 1 L TB liquid culture by
centrifugation (10 000 × g, 30 min, 4°C) and the pellet
were resuspended in cold lysis buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole) at pH 8.0. Lysozyme
(Amresco, Ohio, USA) at the concentration of 0.5 mg/
ml was added to the suspension and incubated on ice
for 30 min. The cells lysates were then disrupted by son-
ication (Misonix Sonicator 3000, Cole-Parmer, Illinois,
USA) on ice for 3 min (30s on/30 s off ). The super-
natant was then treated with DNase1 (Amresco, USA) to
a final concentration of 0.5 μg/ml and incubated at 4°C for
30 min followed by centrifugation at 10 000 × g (Avanti J-
26XPi, Beckman-Coulter, California, USA) for 30 min to
remove the debris. The supernatant was filtered through a
0.45 μm filter membrane (Millipore, Massachusetts, USA).
The filtered lysate of each rPPDK and rGal/GalNAc lec-
tin proteins was purified by using nickel-nitrilotriacetic
acid resin (QIAGEN GmbH, Hilden, Germany). The un-
purified recombinant protein was incubated with the resin
mixture at room temperature for 30 min with gentle shak-
ing, and the resin was transferred into a column. After
washing with a gradient of buffers (50 mM sodium phos-
phate, 500 mM sodium chloride, 20–40 mM imidazole at
pH 8.0), the bound proteins was eluted with the elution
buffer (50 mM sodium phosphate, 500 mM NaCl,
250 mM imidazole at pH 8). Fractions were collected at
500 μL each for up to 10–15 fractions. The purity of the
protein in each fraction was determined by SDS-PAGE.
Fractions with high purity proteins were pooled and con-
centrated using Vivaspin column with 3000 kDa cut-off
(GE Healthcare, Buckinghamshire, UK). The protein con-
centration was determined using Bio-Rad Protein assay re-
agent (Bio-Rad, California, USA) and then stored at −80°C.
Analysis of rPPDK and rGal/GalNAc lectin using
MALDI-TOF/TOF
The specific protein band from SDS–PAGE gel stained
with Coomassie Brilliant Blue G-250 (Bio-Rad, USA) was
excised manually and destained with a commercial
destaining solution (Bio-Rad, USA) at 37°C for 10 minutes;
then washed with 25 mM ammonium bicarbonate
(NH4HCO3, pH 7) and acetonitrile (ACN) for 10 min
each. The gel plug was then reduced with 10 mM DTT
and incubated at 60°C for 30 minutes, alkylated with
55 mM AAT and incubated in the dark for 60 minutes
followed by digestion with 25 μl of 12.5 ng/μl trypsin
(Promega, Wisconsin, USA) and incubated at 37°C for 16 h.
Then, the peptides were collected into a fresh tube and
the gel was further extracted using 50% ACN and 50%
ACN in 0.1% TFA. The sample was then concentrated
using a vacuum concentrator (Thermo Scientific Pierce,
USA) until it reached half the original volume; subse-
quently it was freeze dried overnight (Labconco, Missouri,
USA). Sample clean-up was performed using Zip-Tip col-
umns (Millipore, USA), the peptides was then mixed with
the matrix solution (a-cyano-4-hydroxy-cinnamic acid,
10.0 mg/ml, in 50% acetonitrile and 0.1% trifluoroacetic
acid). Then, 0.6 μl of the mixture was spotted on a
MALDI plate (three spots per sample) and allowed to dry.
The sample was ran on a MALDI-TOF/TOF 5800
analyzer mass spectrometer (AB Sciex, Massachusetts,
USA). One thousand shots were accumulated for MS ana-
lysis. The top fifty most intense parent ions were selected
for MS/MS using air with collision energy of 2 kV and a
collision gas pressure of ~ 1 × 10−6 Torr with 2000–3000
shots accumulated depending on the quality of the spec-
tra. The mass spectra were searched by ProteinPilot soft-
ware (AB Sciex, USA) against AmoebaDB and SwissProt
using MASCOT search engine version 2.1 (Matrix Science,
London, UK). The parameter search allowed for N-
terminal acetylation, cysteine C-terminal carbamido-
methylation and methionine oxidation. One hundred and
fifty ppm and ± 0.4 Da were set for the peptide mass
tolerance and fragment mass tolerance, respectively.
Evaluation of the antigenicity of the recombinant
proteins by Western blotting
The electrophoresed rPPDK and rGal/GalNAc lectin anti-
gens from gels were transferred onto nitrocellulose (NC)
membrane in alkaline transfer buffer (25 mM Tris-base,
190 mM glycine, 10% v/v methanol) using the Trans-Blot
SD (Bio-Rad, USA). The membrane was then incubated in
5× Detector Block solution (KPL, Maryland, USA) for 1 h at
room temperature. The membrane was then washed in
TBST buffer (10 mM Tris–HCl; pH 7.5, 150 mM NaCl,
0.05% Tween-20) in 5, 10 and 15 min. Subsequently, the
NC membrane was cut into multiple strips and incubated
with serum samples from patients with ALA (Group A),
healthy individuals and other diseases as primary antibodies
at dilution 1:100 in TBST overnight at 4°C. Group B serum
samples were not used since these were not from patients
with PCR-proven ALA. It was important to use ‘clear-cut’
samples for proper comparison among IgG-IgG1- and IgG4-
Western blots results since the assay with the higher diag-
nostic potential was subsequently used to develop the lateral
flow test. The excess serum was removed by washing the
strips with TBST.
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Next, the strips were incubated with monoclonal anti-
human IgG-HRP (Invitrogen, USA), IgG1-HRP (Invitrogen,
USA) and IgG4-HRP (Invitrogen, USA) at dilutions of
1:6000, 1:3000 and 1:5000, respectively. The strips were
washed again to remove unbound secondary antibody and
subsequently developed on CL-XPosure film (Thermo
Scientific Pierce, USA) using enhanced chemilumines-
cence (ECL) substrate system (Thermo Scientific Pierce,
USA). The diagnostic sensitivity and specificity of both re-
combinant proteins were calculated using the formulae by
Altman [16]. Sensitivity = TP/(TP + FN) × 100% and speci-
ficity = TN/(TN + FP) × 100%, where TN is the number of
true negatives, TP is the number of true positives, FN is
the number of false negatives, and FP is the number of
false positives.
Development of lateral flow dipstick (LFD)
Conjugation of monoclonal mouse anti human-IgG4
to colloidal gold
The gold colloid was prepared using the seeding-growth
method as previously described [17]. The optical density
(OD) of colloidal gold particles was determined using
UV–vis-NIR spectrophotometer (UV-3600, Shimadzu,
Japan). First, the pH of the gold colloid was adjusted to
the isoelectric point (pH 7) of the monoclonal mouse
anti-human IgG4 antibody (Invitrogen, USA) by adding
0.2 M K2CO3. The optimum amount of anti-human IgG4
to be added to 10 ml of colloidal gold (OD 1.0) was 80 μg;
this was obtained by observing the lowest amount of anti-
body that did not change colour after adding 10% NaCl. It
was gently mixed and incubated for one hour at room
temperature, followed by the addition of 1% bovine serum
albumin (BSA) (Sigma, Missouri, USA) in water (Millipore,
USA) to stabilize the mixture. The excess unconjugated
antibody was removed and the remaining unbound sites
on the colloidal gold were blocked by incubating with 5%
BSA, then washed. The final sedimented colloidal gold
conjugated IgG4 (at OD 20) was resuspended in 1% BSA to
a final volume of 300 μl, then stored at 4°C.
Preparation of lateral flow dipstick (rPPDK-LFD)
The rPPDK was used as the test line by jetting it linearly
onto a Hi-flow Plus 90 membrane card (301 mm length)
with flow rate of 90 ± 23 sec/4 cms (Milipore, USA) using
IsoFlow™ Dispenser (Imagene Technology, New Hampshire,
USA). The equipment was set to dispense the recombinant
antigen at 0.1 μl/mm on the card. The control line
comprised goat anti-mouse IgG (Invitrogen, USA) at
0.5 mg/ml. After the lined reagents have dried, the card
was gently wetted with a blocking solution (Roche Diag-
nostics, Mannheim, Germany). After overnight drying, the
membrane card was cut into 5 mm strips using Index
Cutter-I (A-Point Technologies, Minnesota, USA), then
stored in a dry cabinet at room temperature.
Optimization of antigen concentration and OD of
colloidal gold conjugate
Various antigen concentrations (0.7 mg/ml, 0.8 mg/ml,
0.9 mg/ml, 1.0 mg/ml, 1.25 mg/ml and 1.5 mg/ml) were
tested with the initial OD of 4 to select the optimum
concentration rPPDK which give the highest diagnostic
sensitivity and specificity. Then, the selected rPPDK con-
centration was tested with various ODs of conjugated
antibody, from OD 4 to 10.
Test procedure
Serum sample was diluted 1:2 in phosphate-buffered sa-
line (PBS, pH 7) and 30 μl placed in a well of a microti-
ter plate. The rPPDK-LFD was placed in the well and
the sample was allowed to flow up the dipstick by capil-
lary action. When the sample reached the top of the
strip, the dipstick was dipped into another well contain-
ing 25 μl colloidal gold conjugated anti-human IgG4.
After the line (s) was well-developed, the dipstick was
dipped in another well containing PBS to wash the ex-
cess colloidal gold-conjugated IgG4. The result could be
evaluated within 15 min; the test was recorded as ‘posi-
tive’ when two purplish red lines (control and test lines)
were observed; and recorded ‘negative’ when only one
purplish red line (control line) was observed. The diagnos-
tic sensitivity and specificity of the rPPDK-LFD were de-
termined by testing with sera of patients with ALA
(Groups A and B), healthy individuals and other diseases.
Results
Expression and purification of the rPPDK and rGal/GalNAc
lectin, and confirmation by MALDI-TOF/TOF
The optimal conditions for growth of the recombinant
bacteria were at 30°C with 4 hours of post-induction
with 1 mM IPTG. A satisfactory amount of soluble
rPPDK, 1.5 mg PPDK per litre of culture, was obtained.
SDS-PAGE analyses showed the molecular weight of the
purified rPPDK and rGal/GalNAc lectin proteins were
approximately 98 kDa and 53 kDa, respectively (Figures 1
and 2). The values were in an agreement with the mo-
lecular size predicted from Protparam tool [http://web.
expasy.org/protparam/]. The expressions of rPPDK and
rGal/GalNAc lectin proteins were further confirmed by
Western blot using anti- His-HRP (Novagen, Germany)
as illustrated in Figure 3. The MALDI-TOF/TOF ana-
lysis confirmed the presence of PPDK (Accession no:
EHI_009530) in 98 kDa purified protein band with
protein score of 465 (cut-off value > 70 indicated the
significant hit), nine peptides sequences matched to
the amino acid sequence and sequence coverage of
16%. Meanwhile, the result of MALDI-TOF/TOF ana-
lysis of rGal/GalNAc lectin also confirmed the pres-
ence of this protein (Accession no: EHI_006980) with
protein score of 168 (cut-off value > 70 indicated the
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significant hit), two matched unique peptides and 6%
sequence coverage. The low number of hits may be due to
the fact that Gal/GalNAc lectin is a glycoprotein which is
more difficult to digest using the common digestion
protocol.
Evaluation of the rPPDK and rGal/GalNAc lectin protein
via Western blot
Table 1 summarizes the Western blot results of rPPDK
and rGal/GalNAc lectin using serum samples from pa-
tients with ALA (n = 15), healthy individuals (n = 20) and
patients with other diseases (n = 20). Using IgG, IgG1 and
IgG4 as secondary antibodies, anti-PPDK antibodies were
detected in 13 (86.7%), 12 (80%) and 14 (93.3%) of 15
ALA patients, while anti-Gal/GalNAc lectin antibodies
were detected in 13 (86.7%), 12 (80%) and 14 (93.3%) of
15 ALA patients. The rPPDK showed 97.5%, 97.5% and
100% specificities while rGal/GalNAc lectin showed
97.5%, 87.5% and 95.0% specificities when probed with
IgG, IgG1 and IgG4, respectively. Therefore, the rPPDK
probed with mouse anti-human IgG4 was chosen for de-
velopment of lateral flow dipstick as it showed the highest
diagnostic sensitivity and specificity. Figures 4 and 5 illus-
trated the representative IgG, IgG1 and IgG4 blots of
rPPDK and rGal/GalNAc lectin protein probed with
human serum samples.
Figure 3 Western blot of rPPDK and rGal/GalNAc lectin using
anti-His-HRP (Novagen, Gemany). Lane 1: Precision Plus Protein™
Unstained Standard Marker (Bio-Rad, USA); Lanes 2 and 4: E.coli
whole cells transformed with pET28a(+) vector as a control; Lane 3:
E.coli whole cells expressed rPPDK; Lane 5: E.coli whole cells
expressed rGal/GalNAc lectin.
Figure 2 SDS-PAGE analysis shows the purified rGal/GalNAc lectin.
Lane 1: Precision Plus Protein™ Unstained Standard Marker (Bio-Rad,
USA); Lane 2: Non-induced cell from pET28a/Gal-GalNAc lectin; Lane 3:
Induced cell from pET28a/Gal-GalNAc lectin; Lanes 4–5: purified rGal/
GalNAc lectin protein from elution buffer (250 mM imidazole). Arrow
indicates the recombinant Gal/GalNAc lectin protein (~53 kDa).
Figure 1 SDS-PAGE analysis shows the purified rPPDK. Lane 1:
Precision Plus Protein™ Unstained Standard Marker (Bio-Rad, USA);
Lane 2: Non-induced cell from pET28a/PPDK; Lane 3: Induced cell
from pET28a/PPDK; Lanes 4–5: purified rPPDK protein from elution
buffer (250 mM imidazole). Arrow indicates the recombinant PPDK
protein (~98 kDa).
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Optimum antigen concentration and OD of colloidal gold
conjugate
The optimum concentration of rPPDK for the test line
was 1.25 mg/ml or 0.125 μg per mm of the membrane
card, thus each dipstick contains 0.625 μg rPPDK. The
optimum working concentration for colloidal gold con-
jugated anti-human IgG4 was OD 5. At 25 μl of conju-
gated antibody used per dipstick, this corresponded to
approximately 1.7 μg of anti-human IgG4 per test.
Sensitivity and specificity of rPPDK-LFD
The results of the diagnostic evaluation of rPPDK-LFD
test are summarized in Table 2. Twenty six serum sam-
ples from 30 patients with ALA were tested positive with
rPPDK-LFD with 87% sensitivity and 100% specificity.
Four samples from Groups A and B ALA patients were
found to be negative; one from Group A and 3 from
Group B. From Group A, the same sample was also
negative by IgG4-Western blot. No cross reactivity was
observed from the negative samples. Representative
images of rPPDK-LFD tested with various serum sam-
ples are shown in Figure 6.
Discussion
E. histolytica remains a public health threat in many
parts of the world, especially in the low-resource devel-
oping countries, and has re-emerged in some previously
dormant areas [18]. The most common extraintestinal
manifestation of this infection is ALA, which is associated
with significant morbidity and mortality [19]. Serodiagnosis
is widely used for detection of ALA, and several assays for
the detection of anti-E. histolytica antibodies have been
developed. These include indirect hemagglutination (IHA),
latex agglutination, counter-immunoelectrophoresis (CIE),
amoebic gel diffusion test, indirect immunofluorescence
assay (IFA) and ELISA. Although ELISA is the most prom-
ising in terms of sensitivity [4,8,20], it is usually based on
detection of long-lived IgG antibodies which causes
difficulty to distinguish current from past infections
especially in endemic settings [21]. In addition, most
Figure 4 Representative IgG, IgG1 and IgG4 blots of rPPDK probed with human serum samples. Lane 1: Precision Plus Protein™ Unstained
Standard Marker (Bio-Rad, USA); Lanes 2 to 3: individual serum samples from patients with ALA probed with IgG; Lanes 4 to 5: individual serum
samples probed from patients with ALA probed with IgG1, Lanes 6 to7: individual serum samples from patient with ALA probed with IgG4; Lanes
8, 10 and 12: negative serum samples from healthy individuals probed with IgG, IgG1 and IgG4, respectively; Lanes 9, 11 and 13: negative serum
samples from other disease probed with IgG, IgG1 and IgG4, respectively.
Table 1 Reactivity of the rPPDK and rGal/GalNAc lectin from blots probed with anti-human IgG-HRP, IgG1-HRP and
IgG4-HRP
Recombinant proteins Secondary conjugate
peroxidase
Serum from patients with ALA
(Group A)




IgG 86.7% (13/15) 97.5% (39/40)
IgG1 80.0% (12/15) 97.5% (39/40)
IgG4 93.3% (14/15) 100% (40/40)
Gal/GalNAc lectin IgG 86.7% (13/15) 97.5% (39/40)
(rGal/GalNAc lectin) IgG1 80.0% (12/15) 87.5% (35/40)
IgG4 93.3% (14/15) 95.0% (38/40)
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of the commercial diagnostic tests utilize E. histolytica
crude soluble antigen, thus cross reactions with antibodies
to other infections may be an issue [4,10]. It is also
difficult and time consuming to maintain E. histolytica
trophozoites in culture, to propagate large amounts of the
parasite and consistently produce high quality antigen [7].
Therefore, there is a need to improve the diagnosis of
ALA by using recombinant proteins which are known to
be more specific and reproducible. Recombinant proteins
for E. histolytica antibody detection assays have been
reported, such as 70 kDa rPGM protein, Gal/GalNAc-
Table 2 Sensitivity and specificity of the lateral flow




No. of serum samples that had been tested
for the presence of anti-PPDK antibodies
Positive Negative Total
Positive 26a+b 0 26
(87%)*
Negative 4a+b 40c+d 44
(100%) **
Total 30 40 70
aGroup A sera : Seropositive and E. histolytica DNA detected in patients’ liver
abscess samples.
bGroup B: sera Seropositive and liver abscess samples non-available for
DNA analysis.
cHealthy individuals, Seronegative.
dOther diseases: Seronegative (i.e.: pyogenic liver abscess, malaria,
toxoplasmosis, leptospirosis, hydatidosis, filariasis and typhoid).
*Sensitivity tested with 30 sera from patients with ALA (Groups A and B).
**Specificity tested with 40 sera from healthy individuals and patients with
other diseases.
Figure 5 Representative IgG, IgG1 and IgG4 blots of rGal/GalNAc lectin probed with human serum samples. Lane 1: Precision Plus
Protein™ Unstained Standard Marker (Bio-Rad, USA); Lanes 2 to 3: individual serum samples from patients with ALA probed with IgG; Lanes 4 to 5:
individual serum samples probed from patients with ALA probed with IgG1, Lanes 6 to7: individual serum samples from patient with ALA probed
with IgG4; Lanes 8, 10 and 12: negative serum samples from healthy individuals probed with IgG, IgG1 and IgG4, respectively; Lanes 9, 11 and 13:
negative serum samples from other disease probed with IgG, IgG1 and IgG4, respectively.
Figure 6 Representative rPPDK-LFD strips tested with serum
samples. Lanes 1–3: Lateral flow test strips reacted with serum
samples from patients with ALA; Lane 4: strips reacted with serum
from healthy individual; Lanes 5–6: strips reacted with serum
samples from other diseases (i.e. malaria and pyogenic liver abscess),
C: control line; T: test line.
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specific lectin and serine-rich E.histolytica protein; they
showed sensitivities and specificities ranging from 80%
to 100% when tested using ELISA [7,22-24]. In addition, a
study using recombinant antigen to Gal/GalNAc lectin
(termed as LecA), in a flowthrough rapid test was reported
to be 97% sensitive and 100% specific for diagnosis of
ALA [25]. However there is still a need to convert the
recombinant antigen-based test into a lateral flow immu-
nochromatography test which is rapid, easy to perform and
interpret, and can be transported at room temperature.
In a previous study by our group, PPDK of E. histolytica,
an enzyme involved in the protozoan glycolytic pathway,
was found to be useful for diagnosis of ALA with 82% sen-
sitivity and 100% specificity by Western blot [14,26]. Thus
in this study, PPDK was produced as a recombinant pro-
tein by employing pET expression vector system in E. coli,
and the optimized expression conditions produced 1.5 mg
PPDK per litre of culture. Western blots performed using
serum samples of ALA patients and controls showed that
detection of anti-amoebic IgG4 antibody in samples from
patients with ALA exhibited the highest sensitivity and
specificity, as compared to detection of IgG and IgG1. In
addition, comparison was made between rPPDK and the
previously reported rGal/GalNAc lectin. The latter was a
C-terminal segment of the full protein, which was re-
ported to be highly sensitive and specific for detection of
ALA [27]. In IgG4 assay, the diagnostic sensitivities of
both molecules were similar, however rPPDK demon-
strated better specificity. Thereafter, the rPPDK was used
in the development of an IgG4 lateral flow test in a dip-
stick format. The optimized parameters of the rPPDK-
LFD test and colloidal gold conjugated anti-human IgG4
showed diagnostic sensitivity of 87% and specificity of
100%. With regard to the test sensitivity, 3 of 15 samples
from Group B of the ALA patients were not reactive.
Some possible reasons could be due to extremely low or
lack of anti-PPDK antibodies in these samples; possibly
these were from patients with non-active infection. There
was no cross reactivity with serum samples from healthy
individuals and other diseases, suggesting that this assay is
highly specific for detection of ALA. Further multicentre
validation studies are thus warranted using a larger num-
ber of serum samples from different geographical regions,
inclusion of serum samples from patients infected with
Schistosoma and Fasciola hepatica, patients with other ex-
traintestinal amoebiasis, as well as sera from pre- and
post-treatment patients. When validated, the rapid test
would be useful for disease diagnosis and control; and for
epidemiological studies.
Currently recombinant proteins such as rPPDK and
rGal/GalNAc lectin may not be easily accessible to sci-
entists and diagnostic laboratories as compared to crude
extract of E. histolytica from axenic culture of the para-
site. However, since recombinant proteins hold promise
of greater diagnostic specificity, it is imperative that the
recombinant antigen-based tests should be made com-
mercially available.
Conclusion
The rPPDK-LFD described in this study showed promise
as a rapid diagnostic test for patients suspected of ALA. It
fulfills WHO ASSURED criteria [28,29] for tests that ad-
dress disease control needs i.e. specific, sensitive, simple
and convenient, and results that can be rapidly read by
naked eye. The test can be used in clinical laboratories
which lack specialized equipments or skilled personnel; or
where the low number and frequency of patients do not
justify purchase of ELISA kits.
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